Method of treating an IL-1 related inflammatory disease or condition
View Patent ↗Methods of treating or preventing an IL-1 related disease or condition in a mammal comprising administering an effective amount of an IL-1β binding antibody or IL-1β binding fragment thereof. An IL-1β binding antibody or IL-1β binding fragment thereof is provided comprising the amino acid sequence of SEQ ID NO:28, and related nucleic acids, vectors, cells, and compositions, and a method of preparing an affinity matured IL-1β binding polypeptide is provided. IL-1β binding antibodies or IL-1β binding fragments thereof are provided which have desirable affinity and potency.
1. A method of treating an IL-1 related inflammatory disease or condition in a mammal comprising administering an effective amount of an IL-1β binding antibody or IL-1β binding fragment thereof, said antibody or fragment comprising a heavy chain variable region of SEQ ID NO: 15 and a light chain variable region of SEQ ID NO: 11, wherein the IL-1 related inflammatory disease or condition is rheumatoid arthritis, osteoarthritis, CIAS1 Associated Periodic Syndromes (CAPS), Neonatal Onset Multisystem Inflammatory Disorder (NOMID), Muckle-Wells Syndrome (MWS), Familial Cold Autoinflammatory Syndrome (FCAS), systemic onset juvenile idiopathic arthritis or Stills disease.
2. The method of claim 1 , wherein the IL-1 related disease or condition is rheumatoid arthritis.
3. The method of claim 1 , wherein the IL-1 related disease or condition is osteoarthritis.
4. The method of claim 1 , wherein the IL-1 related disease or condition is CIAS1 Associated Periodic Syndromes (CAPS).
5. The method of claim 1 , wherein the IL-1 related disease or condition is Neonatal Onset Multisystem Inflammatory Disorder (NOMID).
6. The method of claim 1 , wherein the IL-1 related disease or condition is Muckle-Wells Syndrome (MWS).
7. The method of claim 1 , wherein the IL-1 related disease or condition is Familial Cold Autoinflammatory Syndrome (FCAS).
8. The method of claim 1 , wherein the IL-1 related disease or condition is systemic onset juvenile idiopathic arthritis.
9. The method of claim 1 , wherein the IL-1 related disease or condition is Stills disease.
10. The method of claim 1 , wherein the mammal is a human.
11. The method of claim 1 , wherein the effective amount of the antibody or antibody fragment is effective to inhibit IL-1β induced expression of serum IL-6 in an animal by at least 50% as compared to the level of serum IL-6 in the absence of the antibody.
12. A method of treating an IL-1 related inflammatory disease or condition in a mammal comprising administering an effective amount of an IL-1β binding antibody or IL-1β binding fragment thereof, wherein the antibody or fragment binds to human IL-1β with a dissociation constant less than 1 pM, and the antibody or fragment competes with the binding of an antibody comprising the light chain variable region of SEQ ID NO: 11 and the heavy chain variable region of SEQ ID NO: 15, wherein the IL-1 related inflammatory disease or condition is rheumatoid arthritis, osteoarthritis, CIAS1 Associated Periodic Syndromes (CAPS), Neonatal Onset Multisystem Inflammatory Disorder (NOMID), Muckle-Wells Syndrome (MWS), Familial Cold Autoinflammatory Syndrome (FCAS), systemic onset juvenile idiopathic arthritis or Stills disease.
13. The method of claim 12 , wherein the IL-1 related disease or condition is rheumatoid arthritis.
14. The method of claim 12 , wherein the IL-1 related disease or condition is osteoarthritis.
15. The method of claim 12 , wherein the IL-1 related disease or condition is CIAS1 Associated Periodic Syndromes (CAPS).
16. The method of claim 12 , wherein the IL-1 related disease or condition is Neonatal Onset Multisystem Inflammatory Disorder (NOMID).
17. The method of claim 12 , wherein the IL-1 related disease or condition is Muckle-Wells Syndrome (MWS).
18. The method of claim 12 , wherein the IL-1 related disease or condition is Familial Cold Autoinflammatory Syndrome (FCAS).
19. The method of claim 12 , wherein the IL-1 related disease or condition is systemic onset juvenile idiopathic arthritis.
20. The method of claim 12 , wherein the IL-1 related disease or condition is Stills disease.
21. The method of claim 12 , wherein the mammal is a human.
22. The method of claim 12 , wherein the effective amount of the antibody or antibody fragment is effective to inhibit IL-1β induced expression of serum IL-6 in an animal by at least 50% as compared to the level of serum IL-6 in the absence of the antibody.